Update shared on 09 Dec 2025
Analysts have modestly reaffirmed their outlook on Medistim, leaving the price target effectively unchanged at NOK 315, as they continue to point to stable long term growth assumptions and resilient profitability expectations.
Valuation Changes
- Consensus Analyst Price Target remains unchanged at NOK 315, indicating no revision to the central valuation view.
- Discount Rate has fallen slightly from 7.02 percent to 7.01 percent, implying a marginally lower required return.
- Revenue Growth assumptions are effectively unchanged at about 9.69 percent, reflecting stable long term growth expectations.
- Net Profit Margin forecast remains broadly steady at about 23.22 percent, signaling continued confidence in profitability levels.
- Future P/E is unchanged at 34.24x, indicating no change in the implied valuation multiple.
Have other thoughts on Medistim?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.